Press Releases

Hesperos’ multi-organ Human-on-a-Chip System Found Effective for Long-Term Toxicology Testing

by
Hesperos

HESPEROS’ MULTI-ORGAN “HUMAN-ON-A-CHIP” SYSTEM FOUND EFFECTIVE FOR LONG-TERM TOXICOLOGY TESTING Collaboration between L’Oreal, Hesperos and UCF results in further reduction in reliance on animal testing in drug and cosmetics development (ORLANDO, Fla.) The replacement of animals as test subjects is one step closer to reality with the successful testing of multi-organ “human-on-a-chip” models to recapitulate … Read more

Hesperos at NCATS-NASA State-of-the-Science Meeting

by
slas

HESPEROS AT NCATS-NASA STATE-OF-THE-SCIENCE MEETING We’ve been forging new frontiers with our human-on-a-chip multi-organ models—could the next one take us into space?  Last month, we traveled to Washington, DC, to attend a workshop with officials from NASA,NCATS (National Center for Advancing Translational Sciences), and other government officials for a “State-of-the-Science” meeting on 3D tissues and … Read more

Spotlight on Hesperos Innovation at Florida Life Sciences Conference

by
hesperos

We were proud to join hundreds of Florida’s executives, scientists, researchers, investors, legislators, and service providers from the biopharmaceutical, medical device, and healthIT at the recent BioFlorida Annual Conference to celebrate Florida innovation and achievements — and to share some of our own. The conference, held in Ft. Lauderdale on October 14-16, addressed distinct areas … Read more

Hesperos, Inc. Among GROWFL 2018 Florida Companies to Watch

by
growfl

(ORLANDO, Fla.)  Hesperos, Inc. has announced that it has been named one of the 50 statewide companies expected to see significant growth over the next several years by GrowFL. The 50 companies were selected from more than 500 nominees for Florida Companies to WatchSM, a statewide program managed by economic development group GrowFL, in association … Read more

Hesperos Human-on-a-Chip Technology Awarded $4 Million Phase IIb SBIR Grant – the first tissue chip company to receive Phase IIb grant

by
iib

ORLANDO, FLA – September 6, 2018 — Hesperos, Inc. announced today the receipt of a $4 million three-year NIH Phase IIb Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to increase capacity for its novel human-on-a-chip technology, and prepare its systems for regulatory … Read more

Hesperos To Create Multi-Organ Human-On-A-Chip Model to Test Alzheimer’s Drugs

by
Hesperos

Hesperos, Inc., announced today the receipt of a NIH Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) National Institute on Aging (NIA) to help create a new multi-organ “human-on-a-chip” model that can realistically mimic the biology of Alzheimer’s Disease (AD) and the effects of potential new therapies under … Read more

UniChip paper selected as top 10% of papers published in Lab on a Chip

by
hesperos

Dr. Shuler’s “UniChip enables long-term recirculating unidirectional perfusion with gravity-driven flow for microphysiological systems” has been selected by the handling Editor as one of the top 10% of papers published in Lab on a Chip. This selection is based on the exceptionally positive referee reports that the manuscript received during peer review, along with the Editor’s … Read more

Hesperos, Inc. Among GrowFL Florida Companies to Watch Finalists

by
growfl

(ORLANDO, Fla.)  Hesperos, Inc. has announced that it is among the first round of finalists for the 2018 Florida Companies to Watch honor, recently announced by GrowFL.  The awards event – now in its eighth year – honors 50 select second-stage companies from throughout the state for developing valuable products and services, creating quality jobs, enriching communities, … Read more

First Functional Stem-Cell Derived Neuromuscular Junction Model Licensed

by
hesperos

ORLANDO, FLA – April 25, 2018 — Hesperos, Inc. has increased its pioneering human-on-a-chip drug testing capabilities by adding a new in vitro, human-human neuromuscular model to its patented multi-organ microfluidic device systems. Abnormal function of the neuromuscular junction is associated with neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy, and … Read more

Overcoming a Big Barrier: Hesperos CEO awarded for Blood-Brain Barrier Innovation

by
shuler

Getting drugs past the neuroprotective blood-brain barrier (BBB) has been a perplexing problem and formidable challenge for researchers and pharmaceutical companies alike. Hesperos’s creation of a microfluidic model capable of mimicking in vivo characteristics of the blood-brain barrier for prolonged periods was therefore widely welcomed, and recently earned CEO Michael L. Shuler recognition from the American … Read more